NASDAQ:PAVM

PAVmed - PAVM Stock Forecast, Price & News

$0.36

-0.01 (-2.55%)

(As of 03/29/2023 03:57 PM ET)

Add

Compare

Today's Range: $0.35
▼
$0.37
50-Day Range: $0.36
▼
$0.57
52-Week Range: $0.35
▼
$2.34

Volume: 206,964 shs
Average Volume: 465,689 shs
Market Capitalization: $34.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.56

Institutional Ownership

PAVmed MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 900.7% Upside
$3.56 Price Target
Short Interest: Bearish
8.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

796th out of 999 stocks

Surgical & Medical Instruments Industry

80th out of 103 stocks

3.3

Analyst's Opinion

Consensus Rating
PAVmed has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.56, PAVmed has a forecasted upside of 900.7% from its current price of $0.36.
Amount of Analyst Coverage
PAVmed has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.52% of the float of PAVmed has been sold short.
Short Interest Ratio / Days to Cover
PAVmed has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
Change versus previous month
Short interest in PAVmed has recently decreased by 3.12%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
PAVmed does not currently pay a dividend.
Dividend Growth
PAVmed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
PAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.
Environmental Sustainability
The Environmental Impact score for PAVmed is -0.78.

2.7

News and Social Media Coverage

News Sentiment
PAVmed has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for PAVmed this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PAVmed insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.20% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.98% of the stock of PAVmed is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of PAVmed is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PAVmed is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PAVmed has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PAVmed (NASDAQ:PAVM) Stock

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

PAVM Stock News Headlines

March 17, 2023 | finance.yahoo.com

PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know

March 3, 2023 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023

March 29, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 3, 2023 | finance.yahoo.com

PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023

February 15, 2023 | finance.yahoo.com

Here's Why PAVmed Inc. (PAVM) Looks Ripe for Bottom Fishing

January 17, 2023 | finance.yahoo.com

PAVmed and Lucid Diagnostics Provide Strategic Business Update

January 11, 2023 | finance.yahoo.com

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

December 22, 2022 | finance.yahoo.com

PAVmed Partners with Novosound on Ultrasound Imaging Technology

March 29, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

December 1, 2022 | finance.yahoo.com

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

November 18, 2022 | seekingalpha.com

PAVmed Inc. (PAVM) Q3 2022 Earnings Call Transcript

November 15, 2022 | finance.yahoo.com

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

November 11, 2022 | finance.yahoo.com

PAVmed to Participate in BTIG Digital Health Forum

November 10, 2022 | finance.yahoo.com

Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

November 9, 2022 | finance.yahoo.com

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

November 3, 2022 | finance.yahoo.com

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

November 2, 2022 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

October 18, 2022 | marketwatch.com

Pavmed Inc. Common Stock PAVM Pivots Trading Plans and Risk Controls

September 18, 2022 | reuters.com

PAVM.O - PAVmed Inc | Stock Price & Latest News | Reuters

September 10, 2022 | reuters.com

PAVM.OQ - PAVmed Inc | Stock Price & Latest News | Reuters

August 30, 2022 | businesswire.com

PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference - Business Wire

August 17, 2022 | benzinga.com

Nasdaq Down 75 Points After Fed Minutes; Crude Oil Rises 1.5% - Benzinga

August 17, 2022 | finance.yahoo.com

Does PAVmed (NASDAQ:PAVM) Have A Healthy Balance Sheet?

August 17, 2022 | businesswire.com

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results - Business Wire

August 16, 2022 | seekingalpha.com

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03 (NASDAQ:PAVM) - Seeking Alpha

August 16, 2022 | finance.yahoo.com

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results - Yahoo Finance

August 16, 2022 | finance.yahoo.com

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

PAVM Company Calendar

Last Earnings: 8/12/2021
Today: 3/29/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PAVM
CUSIP: N/A
CIK: 1624326
Web: www.pavmed.com
Phone: (212) 949-4319
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.56
High Stock Price Forecast: $8.25
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +911.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,980,000.00
Net Margins: N/A
Pretax Margin: -27,384.09%
Return on Equity: -172.76%
Return on Assets: -79.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.07
Quick Ratio: 1.07

Sales & Book Value

Annual Sales: $380,000.00
Price / Sales: 91.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.09 per share
Price / Book: 3.91

Miscellaneous

Outstanding Shares: 98,420,000
Free Float: 85,429,000
Market Cap: $34.65 million
Optionable: Not Optionable
Beta: 0.88

Key Executives

Lishan Aklog
Chairman & Chief Executive Officer

Dennis M. McGrath
President, Chief Financial Officer & Secretary

Shaun M. O’Neil
Chief Operating Officer & Executive Vice President

Brian J. deGuzman
Chief Medical Officer

James Mitchell
Vice President-Digital Health

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PAVM Stock - Frequently Asked Questions

Should I buy or sell PAVmed stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PAVM shares.
View PAVM analyst ratings or view top-rated stocks.
What is PAVmed's stock price forecast for 2023?: 2 Wall Street research analysts have issued 12 month price targets for PAVmed's shares. Their PAVM share price forecasts range from $1.50 to $8.25. On average, they anticipate the company's stock price to reach $3.56 in the next twelve months. This suggests a possible upside of 911.8% from the stock's current price.
View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts.
How have PAVM shares performed in 2023?: PAVmed's stock was trading at $0.48 at the start of the year. Since then, PAVM shares have decreased by 26.6% and is now trading at $0.3521.
View the best growth stocks for 2023 here.
When is PAVmed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our PAVM earnings forecast.
How were PAVmed's earnings last quarter?: PAVmed Inc. (NASDAQ:PAVM) posted its quarterly earnings results on Thursday, August, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04.
What other stocks do shareholders of PAVmed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP).

What is PAVmed's stock symbol?: PAVmed trades on the NASDAQ under the ticker symbol "PAVM."
Who are PAVmed's major shareholders?: PAVmed's stock is owned by many different institutional and retail investors. Top institutional investors include Wells Fargo & Company MN (0.38%), Millennium Management LLC (0.33%), Levin Capital Strategies L.P. (0.29%), Verition Fund Management LLC (0.14%), Morgan Stanley (0.14%) and Belpointe Asset Management LLC (0.10%). Insiders that own company stock include Lishan Aklog, Matthew Sirovich, Michael J Glennon and Pavmed Inc.
View institutional ownership trends.
How do I buy shares of PAVmed?: Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PAVmed's stock price today?: One share of PAVM stock can currently be purchased for approximately $0.35.
How much money does PAVmed make?: PAVmed (NASDAQ:PAVM) has a market capitalization of $34.65 million and generates $380,000.00 in revenue each year. The company earns $-88,980,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.
How can I contact PAVmed?: PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The official website for the company is www.pavmed.com. The company can be reached via phone at (212) 949-4319 or via email at jmh@pavmed.com.

This page (NASDAQ:PAVM) was last updated on 3/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PAVmed - PAVM Stock Forecast, Price & News

PAVmed MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About PAVmed (NASDAQ:PAVM) Stock

PAVM Stock News Headlines

PAVM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PAVM Stock - Frequently Asked Questions

Overall MarketRank^™